JNJ
Johnson & Johnson
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Johnson & Johnson.
Coverage
Johnson & Johnson's P/E Went 31 to 11 to 23 Without the Market Changing Its Mind. We Published a Chart Doing the Same Thing.
One outsized quarter distorts a trailing P/E twice — once when it arrives, and again four quarters later when it leaves. The second one is invisible, and our own Palo Alto coverage reasoned from it.
Strong Buy on JNJ at $228.26
Insiders cashing out 22.8M shares; technical target $148.29, consensus $230.63.
Johnson & Johnson Guidance
Guides significant oncology sales growth, potentially doubling near-term; supports strong long-term growth.
Biopharma Sentiment Snapped Higher
BPSI index jumped 78 to 90; aligns with price action and deal flow—continued M&A/IPOs expected.
Hospitals in Correction Mode
Stocks down 20-30%; focus on below 20x EV/EBITDA with 20%+ growth—structural tailwind intact.
Earnings release dates
| Quarter | End date | Publication date | Release |
|---|---|---|---|
| 2026 Q2 | 2026-06-30 | 2026-07-15 | Details → |
| 2026 Q1 | 2026-03-31 | 2026-04-22 | Details → |
| 2025 Q4 | 2025-12-31 | 2026-01-21 | Details → |
| 2025 Q3 | 2025-09-30 | 2025-10-14 | Details → |
| 2025 Q2 | 2025-06-30 | 2025-07-16 | Details → |
| 2025 Q1 | 2025-03-31 | 2025-04-15 | Details → |
| 2024 Q4 | 2024-12-31 | 2025-01-22 | Details → |
| 2024 Q3 | 2024-09-30 | 2024-10-15 | Details → |
| 2024 Q2 | 2024-06-30 | 2024-07-17 | Details → |
| 2024 Q1 | 2024-03-31 | 2024-04-16 | Details → |
| 2023 Q4 | 2023-12-31 | 2024-01-23 | Details → |
| 2023 Q3 | 2023-09-30 | 2023-10-17 | Details → |
| 2023 Q2 | 2023-06-30 | 2023-07-20 | Details → |
| 2023 Q1 | 2023-03-31 | 2023-04-18 | Details → |
| 2022 Q4 | 2022-12-31 | 2023-01-24 | Details → |
| 2022 Q3 | 2022-09-30 | 2022-10-18 | Details → |
| 2022 Q2 | 2022-06-30 | 2022-07-19 | Details → |
| 2022 Q1 | 2022-03-31 | 2022-04-19 | Details → |
| 2021 Q4 | 2021-12-31 | 2022-01-25 | Details → |
| 2021 Q3 | 2021-09-30 | 2021-10-19 | Details → |
| 2021 Q2 | 2021-06-30 | 2021-07-21 | Details → |
| 2021 Q1 | 2021-03-31 | 2021-04-20 | Details → |
| 2020 Q4 | 2020-12-31 | 2021-01-26 | Details → |
| 2020 Q3 | 2020-09-30 | 2020-10-13 | Details → |
| 2020 Q2 | 2020-06-30 | 2020-07-16 | Details → |
| 2020 Q1 | 2020-03-31 | 2020-04-14 | Details → |
Company History
Three brothers founded the company in New Brunswick, New Jersey, producing ready-to-use sterile surgical dressings with 14 employees.
Designed to support railroad workers far from medical care, including antiseptic supplies and field use directions.
Earle Dickson combined adhesive tape and gauze to create the first commercial adhesive bandage, sold starting 1921.
Robert Wood Johnson wrote
Cyanide-laced Tylenol led to a nationwide recall of 31 million bottles; company response set industry standards for crisis management.
$30 billion deal, the largest in company history, expanding pharmaceutical capabilities.
$16.6 billion purchase of cardiovascular medical technology company to bolster MedTech segment.
Consumer health division went public as Kenvue in May 2023, with J&J retaining minimal stake by 2024.
Acquired Intra-Cellular Therapies for $14.6B in January 2025, continuing aggressive M&A strategy.
Key Players
showing 6 of 21 · see all leadership & board
